Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

23andMe Holding Co. will be sold to TTAM Research Institute, a genetics-led healthcare company based in California and led by 23andMe co-founder and former CEO Anne Wojcicki.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

A bankruptcy court gave the green light for TTAM Research Institute - a firm launched by 23andMe's co-founder and former CEO ...

Previous reports (including ours) said that a company named Regeneron was supposed to be the buyer, but that deal ended up ...